The Portuguese Pharmacovigilance System
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67 |
Resumo: | In Portugal, the National Pharmacovigilance System (NPS) was created in 1992, completing during this year 20 years of existence. Having been established in a centralized manner, it soon became aware that its geographic decentralization would bring advantages in terms of proximity of the System to health professionals as well as the involvement of the universities. The NPS currently has four regional pharmacovigilance centres, which cover the entire mainland, which became centers of scientific vocation, carrying out pharmacoepidemiological studies in the area of drug safety. Also, they are the guarantee of proper collection, processing and evaluation of spontaneous reports of adverse drug reactions (ADRs), as well as the continuing disclosure of the System among health professionals and promotion of spontaneous reporting. Over these 20 years, the NPS has been adapting to the EU requirements in the area of pharmacovigilance, and is currently a mature and well implemented system, with the objectives of the evaluation of the safety profile of marketed drugs and triggering of actions to reduce the risk of these drugs. From the second half of 2012, new adaptation will be run with the implementation of recent European legislation on Pharmacovigilance, published in December 2010. Among other changes, there is the possibility for consumers to report their suspicious of ADR directly to the NPS (exclusive, so far, to health professionals). This work aims to be a reflection about the evolution of the National Pharmacovigilance System and its growing importance in the protection of public health. |
id |
RCAP_fe6abf686a8c585f5a2d306ae647bb42 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/67 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The Portuguese Pharmacovigilance SystemO Sistema Português de FarmacovigilânciaIn Portugal, the National Pharmacovigilance System (NPS) was created in 1992, completing during this year 20 years of existence. Having been established in a centralized manner, it soon became aware that its geographic decentralization would bring advantages in terms of proximity of the System to health professionals as well as the involvement of the universities. The NPS currently has four regional pharmacovigilance centres, which cover the entire mainland, which became centers of scientific vocation, carrying out pharmacoepidemiological studies in the area of drug safety. Also, they are the guarantee of proper collection, processing and evaluation of spontaneous reports of adverse drug reactions (ADRs), as well as the continuing disclosure of the System among health professionals and promotion of spontaneous reporting. Over these 20 years, the NPS has been adapting to the EU requirements in the area of pharmacovigilance, and is currently a mature and well implemented system, with the objectives of the evaluation of the safety profile of marketed drugs and triggering of actions to reduce the risk of these drugs. From the second half of 2012, new adaptation will be run with the implementation of recent European legislation on Pharmacovigilance, published in December 2010. Among other changes, there is the possibility for consumers to report their suspicious of ADR directly to the NPS (exclusive, so far, to health professionals). This work aims to be a reflection about the evolution of the National Pharmacovigilance System and its growing importance in the protection of public health.O Sistema Nacional de Farmacovigilância (SNF) foi criado em 1992, completando durante o ano corrente 20 anos de existência. Tendo sido estabelecido de forma centralizada, depressa se tomou consciência que a sua descentralização geográfica traria vantagens ao nível da proximidade do Sistema aos profissionais de saúde, bem como do envolvimento das Universidades no mesmo. O SNF conta, atualmente, com quatro unidades regionais de farmacovigilância, que cobrem todo o território continental, e que se tornaram centros com vocação científica, levando a cabo alguns estudos farmacoepidemiológicos na área da segurança do medicamento. Além disso, são o garante da correta recolha, processamento e avaliação das notificações espontâneas de reações adversas a medicamentos (RAM), bem como da permanente divulgação do Sistema junto dos profissionais de saúde e promoção da notificação espontânea. Ao longo destes 20 anos, o SNF foi-se adaptando às exigências comunitárias na área da Farmacovigilância, sendo atualmente um sistema maduro e bem implementado, tendo como objetivos basilares a avaliação do perfil de segurança dos medicamentos comercializados e o desencadeamento de ações para reduzir os riscos da utilização desses medicamentos. A partir do 2º semestre de 2012, decorrerá uma nova adaptação, com a implementação da recente legislação europeia de farmacovigilância, publicada em dezembro de 2010. De entre outras alterações, destaca-se a possibilidade de os consumidores notificarem as suas suspeitas de RAM diretamente ao SNF (exclusiva, até agora, dos profissionais de saúde). Este trabalho pretende constituir uma reflexão sobre a evolução do Sistema Nacional de Farmacovigilância e a sua crescente importância na proteção da Saúde Pública.Ordem dos Médicos2012-08-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67oai:ojs.www.actamedicaportuguesa.com:article/67Acta Médica Portuguesa; Vol. 25 No. 4 (2012): July-August; 241-249Acta Médica Portuguesa; Vol. 25 N.º 4 (2012): Julho-Agosto; 241-2491646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67/55Direitos de Autor (c) 2012 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessHerdeiro, Maria TeresaFerreira, MónicaRibeiro-Vaz, InêsJunqueira Polónia, JorgeCosta-Pereira, Altamiro2022-12-20T10:55:47Zoai:ojs.www.actamedicaportuguesa.com:article/67Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:16:22.009324Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The Portuguese Pharmacovigilance System O Sistema Português de Farmacovigilância |
title |
The Portuguese Pharmacovigilance System |
spellingShingle |
The Portuguese Pharmacovigilance System Herdeiro, Maria Teresa |
title_short |
The Portuguese Pharmacovigilance System |
title_full |
The Portuguese Pharmacovigilance System |
title_fullStr |
The Portuguese Pharmacovigilance System |
title_full_unstemmed |
The Portuguese Pharmacovigilance System |
title_sort |
The Portuguese Pharmacovigilance System |
author |
Herdeiro, Maria Teresa |
author_facet |
Herdeiro, Maria Teresa Ferreira, Mónica Ribeiro-Vaz, Inês Junqueira Polónia, Jorge Costa-Pereira, Altamiro |
author_role |
author |
author2 |
Ferreira, Mónica Ribeiro-Vaz, Inês Junqueira Polónia, Jorge Costa-Pereira, Altamiro |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Herdeiro, Maria Teresa Ferreira, Mónica Ribeiro-Vaz, Inês Junqueira Polónia, Jorge Costa-Pereira, Altamiro |
description |
In Portugal, the National Pharmacovigilance System (NPS) was created in 1992, completing during this year 20 years of existence. Having been established in a centralized manner, it soon became aware that its geographic decentralization would bring advantages in terms of proximity of the System to health professionals as well as the involvement of the universities. The NPS currently has four regional pharmacovigilance centres, which cover the entire mainland, which became centers of scientific vocation, carrying out pharmacoepidemiological studies in the area of drug safety. Also, they are the guarantee of proper collection, processing and evaluation of spontaneous reports of adverse drug reactions (ADRs), as well as the continuing disclosure of the System among health professionals and promotion of spontaneous reporting. Over these 20 years, the NPS has been adapting to the EU requirements in the area of pharmacovigilance, and is currently a mature and well implemented system, with the objectives of the evaluation of the safety profile of marketed drugs and triggering of actions to reduce the risk of these drugs. From the second half of 2012, new adaptation will be run with the implementation of recent European legislation on Pharmacovigilance, published in December 2010. Among other changes, there is the possibility for consumers to report their suspicious of ADR directly to the NPS (exclusive, so far, to health professionals). This work aims to be a reflection about the evolution of the National Pharmacovigilance System and its growing importance in the protection of public health. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-08-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67 oai:ojs.www.actamedicaportuguesa.com:article/67 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/67 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/67/55 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2012 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2012 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 25 No. 4 (2012): July-August; 241-249 Acta Médica Portuguesa; Vol. 25 N.º 4 (2012): Julho-Agosto; 241-249 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130617740263424 |